-
Je něco špatně v tomto záznamu ?
Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter
K. Cerna, D. Duricova, M. Lukas, M. Kolar, N. Machkova, V. Hruba, K. Mitrova, K. Kubickova, M. Kostrejova, J. Jirsa, K. Kastylova, S. Peterka, G. Vojtechova, M. Lukas
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
PubMed Central od 2020
Oxford Journals Open Access Collection od 2019-05-01
ROAD: Directory of Open Access Scholarly Resources od 2019
Odkazy
PubMed
38028954
DOI
10.1093/crocol/otad040
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
BACKGROUND: A subcutaneous formulation of infliximab (IFX-SC) approved to treat patients with inflammatory bowel disease may offer improved efficacy versus intravenous infliximab. METHODS: Patients with refractory Crohn's disease (CD, n = 32) previously treated unsuccessfully with at least 2 biologics were treated with IFX-SC and followed from baseline at Week 0 (W0) to Week 30 (W30). The study's primary endpoint was the treatment's persistence at W30, while secondary goals included the analysis of serum infliximab trough levels (TL IFX), dynamics of anti-IFX antibodies (ATIs), and clinical, serum and fecal markers of CD activity during IFX-SC treatment. RESULTS: Midterm treatment persistence with the continuation of treatment after W30 was 53%. TL IFX median values showed rapid, significant upward dynamics and exceeded 15.5 μg/mL at W30, whereas median ATI levels significantly declined. Among ATI-negative patients at W0 (n = 15), only one showed IFX immunogenicity with newly developed ATIs at W30. Among ATI-positive patients at W0, ATI seroconversion from ATI-positive to ATI-negative status was observed in 10 of 17 patients (58.8%). Patients who had continued IFX-SC treatment at W30 showed significant decreases in C-reactive protein (P = .0341), fecal calprotectin (P = .0002), and Harvey-Bradshaw index (P = .0029) since W0. CONCLUSIONS: Patients with refractory CD previously treated with at least 2 biologics exhibited clinically relevant improvement with IFX-SC, which showed less immunogenic potential than IFX-IV and highly stable TL IFX.
Department of Internal Medicine Hospital Jindrichuv Hradec Jindrichuv Hradec Czech Republic
Institute of Animal Physiology and Genetics Czech Academy of Sciences Libechov Czech Republic
Institute of Pharmacology 1st Faculty of Medicine Charles University Prague Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23022785
- 003
- CZ-PrNML
- 005
- 20240116163132.0
- 007
- ta
- 008
- 240105s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/crocol/otad040 $2 doi
- 035 __
- $a (PubMed)38028954
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Cerna, Karin $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u GENNET, Prague, Czech Republic $1 https://orcid.org/0000000315935899 $7 xx0096040
- 245 10
- $a Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter / $c K. Cerna, D. Duricova, M. Lukas, M. Kolar, N. Machkova, V. Hruba, K. Mitrova, K. Kubickova, M. Kostrejova, J. Jirsa, K. Kastylova, S. Peterka, G. Vojtechova, M. Lukas
- 520 9_
- $a BACKGROUND: A subcutaneous formulation of infliximab (IFX-SC) approved to treat patients with inflammatory bowel disease may offer improved efficacy versus intravenous infliximab. METHODS: Patients with refractory Crohn's disease (CD, n = 32) previously treated unsuccessfully with at least 2 biologics were treated with IFX-SC and followed from baseline at Week 0 (W0) to Week 30 (W30). The study's primary endpoint was the treatment's persistence at W30, while secondary goals included the analysis of serum infliximab trough levels (TL IFX), dynamics of anti-IFX antibodies (ATIs), and clinical, serum and fecal markers of CD activity during IFX-SC treatment. RESULTS: Midterm treatment persistence with the continuation of treatment after W30 was 53%. TL IFX median values showed rapid, significant upward dynamics and exceeded 15.5 μg/mL at W30, whereas median ATI levels significantly declined. Among ATI-negative patients at W0 (n = 15), only one showed IFX immunogenicity with newly developed ATIs at W30. Among ATI-positive patients at W0, ATI seroconversion from ATI-positive to ATI-negative status was observed in 10 of 17 patients (58.8%). Patients who had continued IFX-SC treatment at W30 showed significant decreases in C-reactive protein (P = .0341), fecal calprotectin (P = .0002), and Harvey-Bradshaw index (P = .0029) since W0. CONCLUSIONS: Patients with refractory CD previously treated with at least 2 biologics exhibited clinically relevant improvement with IFX-SC, which showed less immunogenic potential than IFX-IV and highly stable TL IFX.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Duricova, Dana $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000260903522 $7 xx0118363
- 700 1_
- $a Lukas, Martin $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic $u Department of Surgery, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000303565480
- 700 1_
- $a Kolar, Martin $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic
- 700 1_
- $a Machkova, Nadezda $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Hruba, Veronika $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Mitrova, Katarina $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000218363745
- 700 1_
- $a Kubickova, Kristyna $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000312579171
- 700 1_
- $a Kostrejova, Marta $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Internal Medicine, Hospital of the Sisters of Mercy of St. Charles Borromeo, Prague, Czech Republic
- 700 1_
- $a Jirsa, Jakub $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Kastylova, Kristyna $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Peterka, Stepan $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Internal Medicine, Hospital Jindrichuv Hradec, Jindrichuv Hradec, Czech Republic
- 700 1_
- $a Vojtechova, Gabriela $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u ResTrial GastroEndo, Prague, Czech Republic $1 https://orcid.org/000000027911470X $7 xx0229119
- 700 1_
- $a Lukas, Milan $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000214633840 $7 jn19990202012
- 773 0_
- $w MED00213971 $t Crohn's & colitis 360 $x 2631-827X $g Roč. 5, č. 4 (2023), s. otad040
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38028954 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240105 $b ABA008
- 991 __
- $a 20240116163129 $b ABA008
- 999 __
- $a ok $b bmc $g 2036392 $s 1209230
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 5 $c 4 $d otad040 $e 20230725 $i 2631-827X $m Crohn's & colitis 360 $n Crohns Colitis 360 $x MED00213971
- LZP __
- $a Pubmed-20240105